CareCost Prior authorization
Required
Check what the payer requires before you schedule Benlysta.
Prior authorization · diagnosis documentation and standard therapy · covered dosing · site of care
26 payer policy sets · source-linked · reviewed August 2026
Anthem + Systemic lupus erythematosus is shown as a live example until you choose a payer.
This payer requires an approval on file before Benlysta is purchased or infused for this member.
drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization)
Covered under ICD-10 M32.
Individual has a diagnosis of Systemic Lupus Erythematosus per the American College of Rheumatology (ACR)
What opens in CareCost
Anthem / Elevance · Benlysta · Systemic lupus erythematosus
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Anthem / Elevance · Benlysta · Systemic lupus erythematosus
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Benlysta coverage requirements across 26 payer policy sets.
Aetna · Anthem / Elevance · UnitedHealthcare · Cigna · Premera · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →24 of 26 commercial payers require prior authorization, across 296 rules. Most policies turn on documented disease activity and standard therapy already in place, not a sequence of step-therapy trials, and they vary by plan and by indication.
24 require PA · 25 apply a clinical prerequisite · 12 restrict site of care · no payer names a preferred belimumab product
24 of the 26 payers in CareCost’s Benlysta corpus require an approval on file before the drug is purchased or infused.
Two ICD-10 families are covered, one per label indication: systemic lupus erythematosus (M32.9, 26 of 26 payers) and lupus nephritis (M32.14 or M32.15, 22 of 26 payers).
Coverage turns on evidence of active disease, not a lab value alone. Aetna requires “the member is positive for autoantibodies relevant to SLE” and, for lupus nephritis, that it is “confirmed on kidney biopsy”; Anthem requires “disease is active and documented by a SELENA-SLEDAI score greater than or equal to 6…” for SLE and “Class III, IV, or V lupus nephritis…confirmed by renal biopsy” for lupus nephritis. Aetna also requires, for lupus nephritis, that the prescriber be “a rheumatologist, nephrologist, or a specialist in the treatment of lupus nephritis.”
Clinical-prerequisite rules are the largest category in the corpus: 172 of 296, across 25 of 26 payers, and most document that standard therapy is already in place rather than requiring a failed trial. Anthem requires disease activity “while on corticosteroids, antimalarials, or immunosuppressants…for at least the last 30 days.” Where another product is required first, it is either two standard-of-care treatments (BCBS Kansas, South Carolina, Capital BlueCross, Highmark) or a hydroxychloroquine trial (BCBS Arkansas, Minnesota, Mississippi): BCBS Arkansas requires patients “failed, not tolerated, or have a contraindication to a trial (greater than or equal to 3 months) of hydroxychloroquine/chloroquine”; BCBS Minnesota: “Has tried and had an inadequate response to hydroxychloroquine”; CareFirst accepts either “currently receiving standard therapy for SLE…or has tried and had an inadequate response or intolerance to standard therapy.” Only 10 of 26 payers require another product first at all.
16 dosing rules converge on the label’s regimen. BCBS Kansas states it directly: “The IV form is dosed at 10 mg/kg at 2 week intervals for the first 3 doses and at 4 week intervals thereafter.” BCBS Florida instead states an “Approval duration: 1 year.”
Several payers write the label’s limitation of use directly into the policy. BCBS Michigan requires “Patient does not have active central nervous system lupus”; BCBS Minnesota requires “The patient does NOT have severe active central nervous system (CNS) lupus”; BCBS Tennessee excludes “Severe active central nervous system (CNS) lupus (including seizures that are attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis…before initiation of belimumab).” Centene notes: “The efficacy of Benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.” BCBS Nebraska separately restates the label’s own contraindication: “Benlysta is contraindicated in patients that have experienced anaphylaxis with belimumab.”
12 rules restrict where the infusion can happen. Aetna: “Site of Care Utilization Management Policy applies to belimumab (Benlysta).” CareFirst: coverage is provided “when administered in alternative sites such as; physician office, home infusion or ambulatory care.” Blue Shield of California prefers “the home, a physician’s office, or an independent infusion center not associated with a hospital.” BCBS South Carolina: “…may only be authorized to be administered in certain locations (sites of care), such as an infusion center or the patient’s home.” BCBS Arkansas, Kansas, Michigan and Cigna also list J0490 on a site-of-care roster.
Only one rule in the entire corpus renews a Benlysta approval. BCBS Michigan: “Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit.” BCBS Florida instead sets a fixed “Approval duration: 1 year,” and Centene authorizes SLE “…6 months or to member’s renewal date, whichever is longer” — a duration, not a renewal review.
Benlysta’s 26-payer corpus converges on a different shape than a step-therapy drug: an active diagnosis, therapy already underway, and a CNS-lupus exclusion — not a queue of prior products to fail.
| Requirement | What the corpus documents | Basis |
|---|---|---|
| Documented active diagnosis | Autoantibody positivity or a SELENA-SLEDAI score of 6 or more for SLE; a Class III, IV or V biopsy for lupus nephritis | Clinical-prerequisite rules, 172 of 296, across 25 of 26 payers |
| Standard therapy already in place | Antimalarials, corticosteroids or immunosuppressants, continued alongside Benlysta rather than stopped first | Clinical-prerequisite quotes, above |
| Another product first | Two standard-of-care treatments (BCBS Kansas, South Carolina, Capital BlueCross, Highmark) or a hydroxychloroquine trial (BCBS Arkansas, Minnesota, Mississippi) | 10 of 26 payers |
| CNS-lupus exclusion | Active or severe central nervous system lupus excludes coverage at 11 of 26 payers (BCBS Michigan, Minnesota, Tennessee and Centene quoted above) | Contraindication-exclusion rules, 18 total |
| Preferred belimumab product | None named — no belimumab biosimilar exists in this corpus | Preferred-product rules, 0 of 26 payers |
Benlysta is a standard Medicare Part B buy-and-bill drug, priced off the ASP-based fee schedule under J0490 for the FDA-labeled indications below; see the cost estimate for the current rate and the 20% coinsurance after the Part B deductible. Medicare coverage follows Part B buy-and-bill rules: a covered diagnosis, medical necessity, and a claim coded to the indication treated. The subcutaneous autoinjector and prefilled syringe are pharmacy-benefit products billed outside Part B, never under this J0490 claim.
It depends on the payer and plan. In CareCost’s Benlysta corpus, 24 of 26 commercial payers require prior authorization, and coverage turns on documented disease activity and standard therapy already in place rather than a sequence of step-therapy trials. Check this patient’s payer →
Most Benlysta (J0490) policies start with the same core: a covered indication, autoantibody or biopsy documentation, and standard therapy such as antimalarials, corticosteroids or immunosuppressants already in place. At 10 of 26 payers another product must be tried and fail first, and no payer names a preferred belimumab product. CareCost turns the applicable policy into a patient-level checklist, each item with the exact policy language behind it. Open patient clearance →
Yes. Original Medicare pays for Benlysta under Part B as a physician-administered biologic, billed under J0490 and priced off the ASP-based fee schedule. See the cost estimate →
At only 10 of 26 payers. Most policies instead document that standard therapy (antimalarials, corticosteroids or immunosuppressants) is already in place, sometimes for at least 30 days, rather than requiring a documented failure. Where another product is required first it is two standard-of-care treatments or a hydroxychloroquine trial: BCBS Arkansas requires a trial of at least three months, and BCBS Minnesota requires an inadequate response to it. Check this patient’s payer →
Rarely formal for J0490. Only one payer in CareCost’s corpus, BCBS Michigan, writes a Benlysta renewal rule, requiring documentation that the medication is providing clinical benefit. BCBS Florida sets a one-year approval duration and Centene authorizes six months or to the member’s renewal date, whichever is longer; most payers document no reauthorization at all. Check this patient’s payer →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and specialty-drug policies · prior-authorization criteria · site-of-care policies · clinical-prerequisite criteria. Medicare coverage follows Part B buy-and-bill rules, priced off the ASP-based fee schedule. Every CareCost requirement links back to its source policy.